CN1766634A - 一种检测乳腺球蛋白的方法及其试剂盒 - Google Patents
一种检测乳腺球蛋白的方法及其试剂盒 Download PDFInfo
- Publication number
- CN1766634A CN1766634A CN 200510106613 CN200510106613A CN1766634A CN 1766634 A CN1766634 A CN 1766634A CN 200510106613 CN200510106613 CN 200510106613 CN 200510106613 A CN200510106613 A CN 200510106613A CN 1766634 A CN1766634 A CN 1766634A
- Authority
- CN
- China
- Prior art keywords
- mammaglobin
- antibody
- kit
- mammary gland
- breast cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 69
- 239000004816 latex Substances 0.000 claims abstract description 30
- 229920000126 latex Polymers 0.000 claims abstract description 30
- 238000006243 chemical reaction Methods 0.000 claims abstract description 25
- 239000002245 particle Substances 0.000 claims abstract description 24
- 238000012360 testing method Methods 0.000 claims abstract description 23
- 102000006395 Globulins Human genes 0.000 claims abstract description 15
- 108010044091 Globulins Proteins 0.000 claims abstract description 15
- 230000004520 agglutination Effects 0.000 claims abstract description 12
- 210000005075 mammary gland Anatomy 0.000 claims abstract description 12
- 102000004190 Enzymes Human genes 0.000 claims abstract description 11
- 108090000790 Enzymes Proteins 0.000 claims abstract description 11
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000007995 HEPES buffer Substances 0.000 claims abstract description 7
- 238000003757 reverse transcription PCR Methods 0.000 claims abstract 5
- 239000000523 sample Substances 0.000 claims description 53
- 238000001514 detection method Methods 0.000 claims description 33
- 210000002966 serum Anatomy 0.000 claims description 25
- 239000000427 antigen Substances 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 238000002965 ELISA Methods 0.000 claims description 17
- 239000002299 complementary DNA Substances 0.000 claims description 13
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 12
- 108020004999 messenger RNA Proteins 0.000 claims description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- 238000013016 damping Methods 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 238000002372 labelling Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 229920005597 polymer membrane Polymers 0.000 claims description 7
- 239000011148 porous material Substances 0.000 claims description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- 238000009396 hybridization Methods 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 6
- 239000007790 solid phase Substances 0.000 claims description 6
- 108090001008 Avidin Proteins 0.000 claims description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 5
- 229960002685 biotin Drugs 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 230000004523 agglutinating effect Effects 0.000 claims description 4
- 239000003593 chromogenic compound Substances 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 229920000936 Agarose Polymers 0.000 claims description 3
- 238000012408 PCR amplification Methods 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000001962 electrophoresis Methods 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 238000010839 reverse transcription Methods 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 210000004907 gland Anatomy 0.000 abstract description 6
- 238000002156 mixing Methods 0.000 abstract description 5
- 239000000839 emulsion Substances 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 241001215120 Leptospirales Species 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 238000001179 sorption measurement Methods 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 description 60
- 208000026310 Breast neoplasm Diseases 0.000 description 59
- 206010028980 Neoplasm Diseases 0.000 description 25
- 201000011510 cancer Diseases 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 210000001165 lymph node Anatomy 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 102000008857 Ferritin Human genes 0.000 description 3
- 108050000784 Ferritin Proteins 0.000 description 3
- 238000008416 Ferritin Methods 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000007863 gel particle Substances 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102000003848 Uteroglobin Human genes 0.000 description 2
- 108090000203 Uteroglobin Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000000233 bronchiolar non-ciliated Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 102220023256 rs387907547 Human genes 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- HLUNIRWBGNBJOO-UHFFFAOYSA-N 3-ethyl-1-benzothiophene Chemical compound C1=CC=C2C(CC)=CSC2=C1 HLUNIRWBGNBJOO-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000759568 Corixa Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101000583175 Homo sapiens Prolactin-inducible protein Proteins 0.000 description 1
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 1
- 108010066302 Keratin-19 Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101001096236 Mus musculus Prolactin-inducible protein homolog Proteins 0.000 description 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
- 101710094913 Myelin proteolipid protein Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100030350 Prolactin-inducible protein Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001072 progestational effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000018528 secretion by tissue Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (16)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510106613 CN1766634A (zh) | 2005-06-13 | 2005-09-20 | 一种检测乳腺球蛋白的方法及其试剂盒 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510026703.2 | 2005-06-13 | ||
CN200510026703 | 2005-06-13 | ||
CN 200510106613 CN1766634A (zh) | 2005-06-13 | 2005-09-20 | 一种检测乳腺球蛋白的方法及其试剂盒 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1766634A true CN1766634A (zh) | 2006-05-03 |
Family
ID=36742638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200510106613 Pending CN1766634A (zh) | 2005-06-13 | 2005-09-20 | 一种检测乳腺球蛋白的方法及其试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1766634A (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102296119A (zh) * | 2011-09-08 | 2011-12-28 | 苏州友林生物科技有限公司 | 循环血中微量乳腺癌细胞的特异性检测方法及试剂盒 |
CN101261273B (zh) * | 2007-03-06 | 2012-08-22 | 北京美康生物技术研究中心 | 检测早期乳腺癌的酶联免疫吸附试剂盒及其制备方法 |
CN103352077A (zh) * | 2011-09-08 | 2013-10-16 | 苏州友林生物科技有限公司 | 乳腺球蛋白mRNA的检测方法及其试剂 |
CN104407154A (zh) * | 2014-12-05 | 2015-03-11 | 重庆中元生物技术有限公司 | 一种高灵敏度胶乳增强免疫比浊法试剂盒 |
CN108864272A (zh) * | 2018-07-03 | 2018-11-23 | 中国人民解放军军事科学院军事医学研究院 | 一种乳腺珠蛋白a抗原表位及其应用 |
CN110981956A (zh) * | 2019-10-18 | 2020-04-10 | 中国人民解放军军事科学院军事医学研究院 | 识别细胞膜乳腺球蛋白a的单克隆抗体及应用 |
CN111537744A (zh) * | 2020-05-26 | 2020-08-14 | 上海交通大学医学院附属上海儿童医学中心 | 一种基于乳脂肪球膜特性的乳凝集素或粘蛋白1的elisa定量检测方法 |
-
2005
- 2005-09-20 CN CN 200510106613 patent/CN1766634A/zh active Pending
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101261273B (zh) * | 2007-03-06 | 2012-08-22 | 北京美康生物技术研究中心 | 检测早期乳腺癌的酶联免疫吸附试剂盒及其制备方法 |
CN102296119A (zh) * | 2011-09-08 | 2011-12-28 | 苏州友林生物科技有限公司 | 循环血中微量乳腺癌细胞的特异性检测方法及试剂盒 |
CN102296119B (zh) * | 2011-09-08 | 2013-08-07 | 苏州友林生物科技有限公司 | 循环血中乳腺球蛋白mRNA的检测方法及试剂盒 |
CN103352077A (zh) * | 2011-09-08 | 2013-10-16 | 苏州友林生物科技有限公司 | 乳腺球蛋白mRNA的检测方法及其试剂 |
CN104407154A (zh) * | 2014-12-05 | 2015-03-11 | 重庆中元生物技术有限公司 | 一种高灵敏度胶乳增强免疫比浊法试剂盒 |
CN104407154B (zh) * | 2014-12-05 | 2016-03-30 | 重庆中元生物技术有限公司 | 一种高灵敏度胶乳增强免疫比浊法试剂盒 |
CN108864272A (zh) * | 2018-07-03 | 2018-11-23 | 中国人民解放军军事科学院军事医学研究院 | 一种乳腺珠蛋白a抗原表位及其应用 |
CN108864272B (zh) * | 2018-07-03 | 2021-04-27 | 中国人民解放军军事科学院军事医学研究院 | 一种乳腺珠蛋白a抗原表位及其应用 |
CN110981956A (zh) * | 2019-10-18 | 2020-04-10 | 中国人民解放军军事科学院军事医学研究院 | 识别细胞膜乳腺球蛋白a的单克隆抗体及应用 |
CN111537744A (zh) * | 2020-05-26 | 2020-08-14 | 上海交通大学医学院附属上海儿童医学中心 | 一种基于乳脂肪球膜特性的乳凝集素或粘蛋白1的elisa定量检测方法 |
CN111537744B (zh) * | 2020-05-26 | 2023-04-07 | 上海交通大学医学院附属上海儿童医学中心 | 一种基于乳脂肪球膜特性的乳凝集素或粘蛋白1的elisa定量检测方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1189836A (zh) | Dna序列及其编码的乳房特异性乳腺癌蛋白 | |
CN1766634A (zh) | 一种检测乳腺球蛋白的方法及其试剂盒 | |
CN1636139A (zh) | 癌症病人的生物液体中存活素的检测 | |
CN1920520A (zh) | 检测肝癌甲胎蛋白异质体的预装离心柱及含有该离心柱的试剂盒 | |
EP3347712B1 (en) | Methods of identifying drug-modulated polypeptide targets for degradation | |
CN101608240A (zh) | 用于检测人类egfr基因突变的引物、探针及其使用方法 | |
CN1873417A (zh) | 一种用于诊断肺癌的蛋白质芯片 | |
CN109187979B (zh) | 蛋白芯片、蛋白质芯片诊断试剂盒制备及使用方法 | |
US20090226902A1 (en) | Method to Diagnose or Screen for Inflammatory Diseases | |
AU2006209250B2 (en) | Method for diagnosing tumours | |
CN1195869C (zh) | 单克隆抗体、杂交瘤、免疫测定法和诊断试剂盒 | |
CN110187111B (zh) | 一种用于早期贲门癌筛查elisa试剂盒 | |
EP2863224A1 (en) | Kit for diagnosing malignant melanoma | |
JP5858405B2 (ja) | 肺腺がんの予後予測方法、および、肺腺がんの検出キット | |
CN111077312B (zh) | 一组肿瘤相关抗原在制备贲门癌早期筛查试剂盒中的应用 | |
CN110885366B (zh) | 肝癌的肿瘤标志物热休克因子2结合蛋白及其应用 | |
CN1473271A (zh) | 癌转移能力检测剂 | |
CN107266567A (zh) | Lcrmp4单克隆抗体及其制备方法与应用 | |
CN113917160A (zh) | 采用her2抗体免疫荧光法检测乳腺癌循环肿瘤细胞的特异性方法 | |
CN1878876A (zh) | 分子标记 | |
CN1427258A (zh) | 人尿中低密度脂蛋白含量酶联免疫吸附试验试剂盒及制备方法 | |
CN1795385A (zh) | 蛋白masp作为结肠直肠癌标志的用途 | |
JP5316749B2 (ja) | シスプラチン耐性遺伝子診断方法及びシスプラチン治療効果遺伝子診断キット | |
KR20070059373A (ko) | Ndrg2 단백질에 대한 단일클론항체 및 단백질 칩을이용한 정량 측정법 | |
CN110343765B (zh) | 一种用于贲门癌高危人群筛查的snp标志物及试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: CHU PEIGUO Free format text: FORMER OWNER: SHANGHAI JINGTAI BIOLOGY TECHNOLOGY CO., LTD. Effective date: 20080822 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080822 Address after: 907B building, silver mansion, No. four, 11 crossing road, Beijing, Haidian District: 100081 Applicant after: Chu Peiguo Address before: Shanghai City, No. 69, building 25, Guangxi Jinglu 6 floor post encoding: 200233 Applicant before: Shanghai Jingtai Biological Technology Co., Ltd. |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20060503 |